Drugs in Psychiatric Disorders Practice Questions

Q: Which of the following was the PRIMARY indication for which venlafaxine was first FDA approved?

Major depressive disorder. ***Major depressive disorder***- Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) [1], and its primary FDA approval was for the treatment of major depressive disorder [1]- Its mechanism of action, increasing the availability of serotonin and norepinephrine in the brain, is highly effective for managing symptoms of depression [2]- It was first approved by the FDA in 1993 specifically for this indication*Attention deficit hyperactivity disorder (ADHD)*- While some antidepressants are used off-label for ADHD, particularly norepinephrine-reuptake inhibitors like atomoxetine, venlafaxine was not primarily approved for this condition- The mainstays for ADHD treatment are typically stimulants (e.g., methylphenidate, amphetamine) or non-stimulants like atomoxetine*Bipolar disorder*- Venlafaxine can be used as an adjunct in treating the depressive phase of bipolar disorder, but it is not indicated as a monotherapy due to the risk of inducing mania or hypomania- The primary medications for bipolar disorder are mood stabilizers (e.g., lithium, valproate) and atypical antipsychotics*Schizophrenia*- Venlafaxine has no role in the primary treatment of schizophrenia, which is a psychotic disorder- The first-line treatment for schizophrenia involves antipsychotic medications that primarily target dopamine and serotonin receptors

Q: What is the mechanism of action of tianeptine?

AMPA receptor potentiation. ***AMPA receptor potentiation*** - Tianeptine has been shown to modulate **glutamatergic activity** by potentiating **AMPA receptor function**, promoting neuroplasticity [1]. - This effect is thought to contribute to its **antidepressant and anxiolytic properties**, particularly in stress-related neuronal changes [1]. *Mu-opioid receptor agonism* - While tianeptine does exhibit some weak **mu-opioid receptor agonist activity** at higher doses, it is not considered its primary therapeutic mechanism for antidepressant effects. - The opioid effects are usually associated with its **abuse potential** and are distinct from its primary antidepressant action. *Serotonin reuptake enhancement* - Tianeptine is unique among antidepressants for its property of **enhancing serotonin reuptake**, rather than inhibiting it. - Although it increases serotonin reuptake, this effect alone does not fully explain its antidepressant action, and its **glutamatergic modulation** is considered more critical. *NMDA receptor antagonism* - **NMDA receptor antagonism** is associated with drugs like ketamine, which have rapid antidepressant effects by blocking the receptor [2]. - Tianeptine does not directly act as an NMDA receptor antagonist; instead, it influences synaptic plasticity through **AMPA receptor modulation**.

Q: The clinical effects of antidepressant drugs are mainly based on?

Change in neurotransmitter receptor sensitivity. ***B. Change in neurotransmitter receptor sensitivity*** - While many antidepressants initially alter neurotransmitter levels by blocking reuptake, their delayed therapeutic effects (weeks) are thought to be mediated by **adaptive changes** in postsynaptic receptor sensitivity and gene expression, leading to **downregulation of hypersensitive receptors**. - This **receptor plasticity** is crucial for long-term clinical improvement, as the brain adapts to sustained changes in neurotransmitter availability. *A. Reduction in neurotransmitter levels* - This option is incorrect as antidepressants generally aim to **increase** the functional availability of **neurotransmitters** like serotonin and norepinephrine within the synaptic cleft. - A reduction in neurotransmitter levels would typically exacerbate depressive symptoms, not alleviate them. *C. Modification of neurotransmitter signaling pathways* - While antidepressants do ultimately affect intracellular signaling pathways, this is often a **downstream consequence** of changes in receptor sensitivity and neurotransmitter binding, rather than the primary *main* basis of their clinical effects. - This option is broader and less precise than the change in receptor sensitivity, missing the direct impact on how neurons respond to available neurotransmitters. *D. Inhibition of neurotransmitter reuptake* - This describes the **initial and acute mechanism of action** for many antidepressant classes (e.g., SSRIs, SNRIs) by increasing the concentration of neurotransmitters in the synaptic cleft. - However, the **clinical antidepressant effects** often take several weeks to manifest, suggesting that this acute increase in neurotransmitter availability is not the sole or primary basis for long-term symptom relief, but rather initiates the adaptive changes in receptor sensitivity.

Q: All the following drugs are used to prevent relapse and maintain abstinence in cases of alcohol use disorder except?

Propranolol. ***Propranolol*** - **Propranolol** is a **beta-blocker** primarily used to treat conditions like hypertension, angina, and anxiety. - While it can help manage some **symptoms associated with alcohol withdrawal**, such as tremors and tachycardia, it is **not indicated or effective for preventing relapse or maintaining abstinence** from alcohol use disorder. *Disulfiram* - **Disulfiram** works by inhibiting **acetaldehyde dehydrogenase**, leading to an unpleasant accumulation of acetaldehyde if alcohol is consumed. - This adverse reaction serves as a **deterrent** to drinking alcohol, helping to prevent relapse [1], [2]. *Acamprosate* - **Acamprosate** is believed to restore the balance between **excitatory (glutamate)** and **inhibitory (GABA)** neurotransmission in the brain, which is often disrupted in alcohol dependence. - It helps reduce cravings and the **negative reinforcement** associated with protracted withdrawal, aiding in the maintenance of abstinence [1]. *Naltrexone* - **Naltrexone** is an **opioid receptor antagonist** that works by blocking the euphoric and pleasurable effects of alcohol [1]. - By reducing the **rewarding effects of alcohol**, it helps decrease cravings and subsequently the risk of relapse [1].

Q: In which condition is Atomoxetine primarily indicated?

ADHD. ***ADHD*** - **Atomoxetine** is a **norepinephrine reuptake inhibitor** primarily used for the treatment of **Attention-Deficit/Hyperactivity Disorder (ADHD)** in children, adolescents, and adults [1]. - It helps improve symptoms such as **inattention**, **hyperactivity**, and **impulsivity** by increasing the concentration of norepinephrine in the brain [1], [2]. *Treatment of nocturnal enuresis* - While some medications for **ADHD** (like **imipramine**) can be used off-label for **nocturnal enuresis**, atomoxetine is **not a primary indication** for this condition [3]. - Management of **nocturnal enuresis** typically involves behavioral interventions, desmopressin, or tricyclic antidepressants [3]. *Management of temper tantrums* - **Temper tantrums** are primarily behavioral issues and are generally managed through **behavioral therapy** and parenting strategies. - **Atomoxetine** is not indicated as a primary treatment for temper tantrums; if tantrums are a symptom of an underlying disorder like ADHD, addressing the ADHD might indirectly help. *Treatment of patent ductus arteriosus* - **Patent ductus arteriosus (PDA)** is a cardiovascular condition typically seen in newborns, involving a persistent opening between the aorta and pulmonary artery. - Treatment for PDA usually involves **NSAIDs (like indomethacin or ibuprofen)** or surgical ligation, not atomoxetine.

Q: Which of the following statements about aripiprazole is true?

It is used in the treatment of acute mania. ***It is used in the treatment of acute mania*** - Aripiprazole is a **second-generation antipsychotic** approved for the treatment of **acute manic and mixed episodes** associated with bipolar I disorder. - This is a **major FDA-approved indication** and represents one of its most clinically significant uses, making it the best answer among the true statements. - Its efficacy in stabilizing mood through its unique partial agonism at dopamine D2 and serotonin 5-HT1A receptors, along with antagonism at 5-HT2A receptors, makes it suitable for this indication. *It has 5HT1A partial agonist action* - This statement is **factually TRUE** - aripiprazole does have **5-HT1A partial agonist action** as part of its pharmacological profile. - However, this mechanistic detail alone does not represent its primary clinical significance or most distinguishing therapeutic feature. - Its unique mechanism also involves **D2 partial agonism** and 5-HT2A antagonism. *It has low sedating potential* - This statement is also **TRUE** - aripiprazole is well-established as having **low sedating potential** compared to most other antipsychotics. - This is actually one of its **distinguishing advantages** and a key feature that differentiates it from highly sedating antipsychotics like quetiapine or olanzapine. - While sedation can occur in some patients, it is relatively uncommon, and the low sedation profile is a recognized clinical benefit. *Only antipsychotic with D2 partial agonist activity* - This statement is **FALSE** - aripiprazole was one of the first antipsychotics with significant **D2 partial agonist activity**, but it is **not the *only* one**. - Other antipsychotics, such as **brexpiprazole** and **cariprazine**, also exhibit D2 partial agonist activity, distinguishing them from traditional D2 antagonists.

Q: Which receptor is most commonly targeted by typical antipsychotics?

D2. ***Correct: D2*** - **Typical antipsychotics** (first-generation antipsychotics) primarily exert their therapeutic effects by blocking **dopamine D2 receptors** in the mesolimbic pathway, thereby reducing positive symptoms of psychosis such as hallucinations and delusions. - The degree of **D2 receptor blockade** correlates directly with **clinical efficacy** for typical antipsychotics. - High-potency typical antipsychotics like haloperidol have strong D2 receptor affinity, while low-potency agents like chlorpromazine also work primarily through D2 blockade. - D2 blockade in the nigrostriatal pathway is responsible for extrapyramidal side effects (EPS), a hallmark of typical antipsychotics. *Incorrect: D1* - **D1 receptors** are dopaminergic receptors involved in cognitive and motor functions, but their blockade is not the primary mechanism of action of typical antipsychotics. - While some antipsychotics may have D1 affinity, this is not what defines typical antipsychotics or drives their therapeutic efficacy. *Incorrect: D3* - **Dopamine D3 receptors** are involved in the limbic system and may play a role in some antipsychotic effects, but they are not the primary target for **typical antipsychotics**. - Some newer atypical antipsychotics have higher affinity for D3 receptors, but this is not characteristic of first-generation typical agents. *Incorrect: D4* - **D4 receptors** have high affinity for certain atypical antipsychotics like **clozapine**, but this is not the main receptor target for **typical antipsychotics**. - D4 receptor selectivity is more associated with atypical rather than typical antipsychotic profiles.

Q: What electrolyte imbalance is commonly associated with lithium use?

Hypercalcemia. ***Hypercalcemia*** - Long-term lithium therapy can lead to an increased risk of developing **primary hyperparathyroidism** (occurs in approximately 10% of chronic users), which subsequently causes hypercalcemia. - Lithium can affect the **set point of the calcium-sensing receptor** in the parathyroid glands, leading to inappropriate secretion of parathyroid hormone (PTH). - This is a **well-recognized complication** of chronic lithium therapy requiring monitoring of calcium and PTH levels. *Hyponatremia* - **Hyponatremia** is actually a frequently encountered electrolyte disturbance with lithium use, occurring through multiple mechanisms: - Lithium-induced **nephrogenic diabetes insipidus** leading to polyuria, polydipsia, and potential dehydration - Interaction with **thiazide diuretics** (which are sometimes used to treat lithium-induced polyuria, paradoxically) - SIADH-like effects in some patients - However, in the context of this examination question, **hypercalcemia due to hyperparathyroidism** is considered the characteristic chronic complication specifically linked to lithium's unique mechanism of action. *Hyperkalemia* - **Hyperkalemia** is not a commonly reported electrolyte imbalance specifically associated with lithium use. - While lithium can affect renal function and cause **renal tubular dysfunction**, this does not typically manifest as hyperkalemia. *Hypokalemia* - **Hypokalemia** is not typically associated with lithium use. - It is more commonly caused by diuretic use, vomiting, or diarrhea rather than lithium therapy directly.

Q: A patient was recently started on Fluphenazine. A few weeks later, he developed tremors, rigidity, bradykinesia, and excessive salivation. The first line of management for this patient is

Trihexyphenidyl. ***Trihexyphenidyl*** - The patient is exhibiting symptoms consistent with drug-induced **parkinsonism** caused by fluphenazine, an antipsychotic. - **Anticholinergics** like trihexyphenidyl are the **first-line treatment** for drug-induced parkinsonism by blocking muscarinic receptors in the striatum, restoring the dopamine-acetylcholine balance. *Selegiline (MAO-B inhibitor)* - Selegiline is used in Parkinson's disease to **increase dopamine levels** by inhibiting its breakdown, but it is not the first-line treatment for drug-induced parkinsonism where the issue is receptor blockade. - Its primary role is in **idiopathic Parkinson's disease** as an adjunctive therapy or for early symptom control, not for antipsychotic-induced extrapyramidal symptoms. *Amantadine* - Amantadine is an **NMDA receptor antagonist** and dopamine reuptake inhibitor used in Parkinson's disease. - While it has some efficacy in drug-induced parkinsonism, it is generally considered **second-line** after anticholinergics and is more effective for dyskinesia in idiopathic Parkinson's disease. *Pramipexole (Dopamine agonist)* - Dopamine agonists work by **directly stimulating dopamine receptors**, which would exacerbate the effects of D2 receptor blockade by fluphenazine. - They are used for **idiopathic Parkinson's disease** and restless legs syndrome, but are typically avoided in drug-induced parkinsonism.

Question 1

Which of the following is true about ziprasidone?

Accepted Answer

Lower risk of extrapyramidal symptoms compared to typical antipsychotics

Answer

Has anti-depressant properties

Answer

Not safe in cardiac patients due to QT prolongation risk

Answer

Commonly causes significant weight gain

Question 2

Which of the following was the PRIMARY indication for which venlafaxine was first FDA approved?

Accepted Answer

Major depressive disorder

Answer

Bipolar disorder

Answer

Attention deficit hyperactivity disorder (ADHD)

Answer

Schizophrenia

Question 3

What is the mechanism of action of tianeptine?

Accepted Answer

AMPA receptor potentiation

Answer

NMDA receptor antagonism

Answer

Serotonin reuptake enhancement

Answer

Mu-opioid receptor agonism

Question 4

The clinical effects of antidepressant drugs are mainly based on?

Accepted Answer

Change in neurotransmitter receptor sensitivity

Answer

Reduction in neurotransmitter levels

Answer

Modification of neurotransmitter signaling pathways

Answer

Inhibition of neurotransmitter reuptake

Question 5

All the following drugs are used to prevent relapse and maintain abstinence in cases of alcohol use disorder except?

Accepted Answer

Propranolol

Answer

Acamprosate

Answer

Naltrexone

Answer

Disulfiram

Question 6

In which condition is Atomoxetine primarily indicated?

Accepted Answer

ADHD

Answer

Treatment of nocturnal enuresis

Answer

Management of temper tantrums

Answer

Treatment of patent ductus arteriosus

Question 7

Which of the following statements about aripiprazole is true?

Accepted Answer

It is used in the treatment of acute mania

Answer

It has low sedating potential

Answer

It has 5HT1A partial agonist action

Answer

Only antipsychotic with D2 partial agonist activity

Question 8

Which receptor is most commonly targeted by typical antipsychotics?

Accepted Answer

D2

Answer

D1

Answer

D3

Answer

D4

Question 9

What electrolyte imbalance is commonly associated with lithium use?

Accepted Answer

Hypercalcemia

Answer

Hyponatremia

Answer

Hyperkalemia

Answer

Hypokalemia

Question 10

A patient was recently started on Fluphenazine. A few weeks later, he developed tremors, rigidity, bradykinesia, and excessive salivation. The first line of management for this patient is

Accepted Answer

Trihexyphenidyl

Answer

Amantadine

Answer

Selegiline (MAO-B inhibitor)

Answer

Pramipexole (Dopamine agonist)

Drugs in Psychiatric Disorders — MCQs

Drugs in Psychiatric Disorders — MCQs

On this page

Practice by Chapter

Want unlimited practice?